During phase II study in a group of patients with NAFLD and type 2 diabetes, OCA improved central and peripheral insulin sensitivity and reduced parameters of hepatic inflammation and fibrosis yielding promising results in larger studies (Mudaliar et al., 2013). Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.